Kantonsspital St.Gallen
login

publications

Stefan Diem

title  
 
Favara D M, Spain L, Au L, Clark J, Daniels E, Diem S, Chauhan D, Turajlic S, Powell N, Larkin J M, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open 2020; 5:.
   
Herbrand A K, Schmitt A M, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord K A, Novak U, Sricharoenchai S, Hemkens L G, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019; 4:e000596.
   
Diem S, Fässler M, Bomze D, Ali O H, Berner F, Niederer R, Hillmann D, Mangana J, Levesque M P, Dummer R, Risch L, Recher M, Risch M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
   
Safroneeva E, Saner C, Rossel J B, Golay D, Pittet V, Godat S, Diem S, Aepli P, sauter r, Borovicka J, Burgmann K, Juillerat P, Netzer P, Sendensky A, Hruz P, Girardin M, Biedermann L, Greuter T, Vavricka S, Michetti P, Mueller C, Straumann A, Schoepfer A M, Swiss EoE Cohort Study Group . Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS). Inflamm Intest Dis 2018; 2:163-170.
   
schmid s, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 2018;.
   
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A J, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111:176-181.
   
Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A J, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. JAAD Case Rep 2016; 2:415-417.
   
Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, Larkin J. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 2016; 114:256-61.
   
Diem S, Keller F, Rüesch R, Maillard S A, Speiser D E, Dummer R, siano m, Urner-Bloch U, Goldinger S M, Flatz L, Diem S. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.
   
Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L E, Speiser D E, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016; 5:e1231292.
   
Diem S, Ess S, cerny t, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med 2014; 25:577-82.
   
Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, cerny t. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.
   
 
page 1 of 1